Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$8.75 USD
+0.01 (0.11%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $8.75 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARQT 8.75 +0.01(0.11%)
Will ARQT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ARQT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARQT
Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?
Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?
ARQT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
Other News for ARQT
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)
Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts
Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)
Arcutis Appoints David Topper as Chief Financial Officer
Arcutis Biotherapeutics appoints CFO